Gout

Novilla strives to deliver effective pain therapeutics locally to avoid systemic side effects

Acute gouty flare is a serious debilitating condition causing excruciating pain with an unmet medical need. Despite several drugs on the market to manage chronic gout prophylactically, patients still suffer on average, three acute gout flare-ups every year that last for 5-7 days. Acute gouty flare is an intensely painful and disabling inflammatory arthritis, usually involving a single joint but occasionally involving two or more joints. Without therapy, the gout flare usually lats a few days to several weeks, particularly in early disease. Symptoms do improve quickly with administration of NSAIDs, Steroids, or Colchicine. However, all of these drugs have significant systemic side effects that make these drugs less desirable and poorly tolerated.

  • 9.2 million Americans suffer from gout

  • 37% repeat flare up rate within 3 years

  • 30% of gout patients are prescribed an opioid for pain relief

  • Hospitalizations due to gout have doubled in the US

83%

Gout Pain Relief

In a Phase 1 Clinical trial, gout patients were treated with NOV-1776 and 83% of gout patients experienced gout pain relief.

2 Days

Reduction of Gout Flare

Compare to the standard of care, patients treated with NOV-1776 experienced a reduction of gouty flare in under 2 days on average

212%

Increase in Efficacy

Novilla’s topical pain therapeutic yields stronger efficacy compared to current standard of care.

100%

Saw a Pain Improvement

100% of patients reported a pain reduction of over 50% by the end of the study duration.

0%

Adverse Effects or Rescue Medication

In a clinical trial, 0% of patients experienced GI or Renal adverse events. Additionally, none of the patients required rescue medication

<1%

Systemic Absorption

The systemic concentration of active pharmaceutical agent was below 1% while still administering an effiacious dose to local tissues.